Rising Healthcare Costs And Patent Expiry Will Crush RNAi Prospects
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 14 Analysts
Published
07 Aug 25
Updated
16 Aug 25
AnalystLowTarget's Fair Value
US$17.00
25.5% overvalued intrinsic discount16 Aug
US$21.33
1Y
-13.9%7D
4.0%